Report Detail

Pharmaceuticals & Healthcare Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2018

  • RnM2474166
  • |
  • 07 May, 2020
  • |
  • Global
  • |
  • 83 Pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Overview

              Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Products under Development by Companies

                      Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Therapeutics Assessment

                        Assessment by Target

                          Assessment by Mechanism of Action

                            Assessment by Route of Administration

                              Assessment by Molecule Type

                                Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Companies Involved in Therapeutics Development

                                  Asklepion Pharmaceuticals LLC

                                    AstraZeneca Plc

                                      Bristol-Myers Squibb Co

                                        Cyclerion Therapeutics Inc

                                          Gilead Sciences Inc

                                            Global Blood Therapeutics Inc

                                              KM Biologics Co Ltd

                                                NicOx SA

                                                  Novartis AG

                                                    NuvOx Pharma LLC

                                                      Prolong Pharmaceuticals LLC

                                                        Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Drug Profiles

                                                          apadamtase alfa - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  apixaban - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          crizanlizumab - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  inclacumab - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          L-Citrulline - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  naproxcinod - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          NVX-508 - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  olinciguat - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          regadenoson - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  Sanguinate - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          ticagrelor - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Dormant Projects

                                                                                                                                                    Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Discontinued Products

                                                                                                                                                      Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Product Development Milestones

                                                                                                                                                        Featured News & Press Releases

                                                                                                                                                          Dec 20, 2019: Novartis wins Medicaid approval for new sickle cell drug in key US states

                                                                                                                                                            Nov 18, 2019: FDA approves Novartis’ Adakveo for sickle cell disease patients

                                                                                                                                                              Jul 16, 2019: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

                                                                                                                                                                Jan 09, 2018: Prolong Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference

                                                                                                                                                                  Dec 13, 2017: Prolong Pharma Announces Completion of Enrollment in Phase II Study of SANGUINATE in the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis in an Ambulatory Setting

                                                                                                                                                                    Nov 08, 2017: Prolong Pharmaceuticals to Present New Research on SANGUINATE, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis in Patients with Sickle Cell Disease, at ASH Annual Meeting

                                                                                                                                                                      Feb 01, 2017: A multiple drug approach to preventing sickle cell crisis

                                                                                                                                                                        Aug 19, 2013: Selexys Pharmaceuticals Initiates SUSTAIN Phase 2 Clinical Trial in Sickle Cell Patients with Pain Crises

                                                                                                                                                                          Appendix

                                                                                                                                                                            Methodology

                                                                                                                                                                              Coverage

                                                                                                                                                                                Secondary Research

                                                                                                                                                                                  Primary Research

                                                                                                                                                                                    Expert Panel Validation

                                                                                                                                                                                      Contact Us

                                                                                                                                                                                        Disclaimer

                                                                                                                                                                                        Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2020

                                                                                                                                                                                        Summary

                                                                                                                                                                                        Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2020, provides an overview of the Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline landscape.

                                                                                                                                                                                        Vaso-occlusive crisis associated with sickle cell disease is a painful episode that occurs in people who have sickle cell anemia. Symptoms include fever, pain, fatigue, abdominal pain and swelling, headaches, shortness of breath, dehydration and infection. Treatment includes NSAIDs, acetaminophen, blood transfusion and surgery.

                                                                                                                                                                                        Report Highlights

                                                                                                                                                                                        Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

                                                                                                                                                                                        The Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 2, 3, 1 and 4 respectively.

                                                                                                                                                                                        Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

                                                                                                                                                                                        Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                        Scope

                                                                                                                                                                                        - The pipeline guide provides a snapshot of the global therapeutic landscape of Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
                                                                                                                                                                                        - The pipeline guide reviews pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
                                                                                                                                                                                        - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
                                                                                                                                                                                        - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
                                                                                                                                                                                        - The pipeline guide reviews key companies involved in Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics and enlists all their major and minor projects.
                                                                                                                                                                                        - The pipeline guide evaluates Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
                                                                                                                                                                                        - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
                                                                                                                                                                                        - The pipeline guide reviews latest news related to pipeline therapeutics for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular)

                                                                                                                                                                                        Reasons to Buy

                                                                                                                                                                                        - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
                                                                                                                                                                                        - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
                                                                                                                                                                                        - Find and recognize significant and varied types of therapeutics under development for Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular).
                                                                                                                                                                                        - Classify potential new clients or partners in the target demographic.
                                                                                                                                                                                        - Develop tactical initiatives by understanding the focus areas of leading companies.
                                                                                                                                                                                        - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
                                                                                                                                                                                        - Formulate corrective measures for pipeline projects by understanding Vaso-Occlusive Crisis Associated With Sickle Cell Disease (Cardiovascular) pipeline depth and focus of Indication therapeutics.
                                                                                                                                                                                        - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
                                                                                                                                                                                        - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


                                                                                                                                                                                        Summary:
                                                                                                                                                                                        Get latest Market Research Reports on Vaso-Occlusive Crisis Associated With Sickle Cell Disease. Industry analysis & Market Report on Vaso-Occlusive Crisis Associated With Sickle Cell Disease is a syndicated market report, published as Vaso-Occlusive Crisis Associated With Sickle Cell Disease - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Vaso-Occlusive Crisis Associated With Sickle Cell Disease market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                                                        Last updated on

                                                                                                                                                                                        REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                                                        Purchase this Report

                                                                                                                                                                                        $2,000.00
                                                                                                                                                                                        $4,000.00
                                                                                                                                                                                        $6,000.00
                                                                                                                                                                                        1,541.13
                                                                                                                                                                                        3,082.26
                                                                                                                                                                                        4,623.39
                                                                                                                                                                                        1,700.57
                                                                                                                                                                                        3,401.15
                                                                                                                                                                                        5,101.72
                                                                                                                                                                                        210,746.00
                                                                                                                                                                                        421,492.00
                                                                                                                                                                                        632,238.00
                                                                                                                                                                                        146,648.20
                                                                                                                                                                                        293,296.40
                                                                                                                                                                                        439,944.60
                                                                                                                                                                                        Credit card Logo

                                                                                                                                                                                        Related Reports


                                                                                                                                                                                        Reason to Buy

                                                                                                                                                                                        Request for Sample of this report